RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 301–400 of 1,003
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines
Barnabas, N., & Cohen, D. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/872743 · Cited by 85
“Since activating RAS isoforms have been reported for KRAS, HRAS and NRAS, Ras mutations have been identi�ed in many tumor types and show tissue speci�city [70].”
BackgroundIvanov, S. V., Panaccione, A., Brown, B. T., Guo, Y. P., Moskaluk, C. A., Wick, M. J., Brown, J. L., Ivanova, A. V., Issaeva, N., El‐Naggar, A. K., et al. (2012) · Oncogene · doi:10.1038/onc.2012.377 · Cited by 79
PI3K: A Crucial Piece in the RAS Signaling Puzzle
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 84
“The mechanisms by which RAS activation initiates and sustains proangiogenic processes are complex and rely on the modulation of endothelial growth factors and also on the increase of local inflammation and stromal remodeling (Pylayeva-Gupta et al. 2011).”
BackgroundThe Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
“They are preferentially located at different membrane microdomains (8) and are not functionally redundant (9 – 20).”
BackgroundKhan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 83
SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype
Motta, M., Fasano, G., Gredy, S., Brinkmann, J., Bonnard, A. A., Şimşek‐Kiper, P. Ö., Güleç, E. Y., Essaddam, L., Ütine, G. E., Prandi, I. G., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.09.007 · Cited by 86
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 86
ROS, autophagy, mitochondria and cancer: Ras, the hidden master?
Bellot, G. L., Liu, D., & Pervaiz, S. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.06.007 · Cited by 81
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
Crook, Z. R., Sevilla, G. P., Friend, D., Brusniak, M.-Y., Bandaranayake, A. D., Clarke, M., Gewe, M., Mhyre, A. J., Baker, D., Strong, R. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02098-8 · Cited by 78
Rare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
“Extending these results one step further, we speculate that poor expression imposed by rare codons may increase the likelihood that an oncogenic mutation in KRAS will lead to proliferation instead of growth arrest, which may account for the high frequency of mutations in KRAS compared with those occurring in the other…”
Stress granules: functions and mechanisms in cancer
Zhou, H., Luo, J., Mou, K., Peng, L., Li, X., Lei, Y., Wang, J., Lin, S., Luo, Y., & Li, X. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01030-6 · Cited by 80
“These RAS genes constitute some of the most commonly mutated genes in tumor cell, with mutations in RAS genes detected in approximately 30% of all tumors [42].”
BackgroundMolecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Johnson, D. B., Smalley, K. S. M., & Sosman, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3270 · Cited by 87
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J., Bardelli, A., Torrance, C., Lord, C. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149099 · Cited by 78
Clinical Trials and Progress in Metastatic Colon Cancer
Mody, K., & Bekaii‐Saab, T. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.008 · Cited by 80
Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression
Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 81
Invited review: Small GTPases and their GAPs
Mishra, A. K., & Lambright, D. G. (2016) · Biopolymers · doi:10.1002/bip.22833 · Cited by 81
Smyd3-associated regulatory pathways in cancer
Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 88
New tricks for human farnesyltransferase inhibitor: cancer and beyond
Wang, J., Yao, X., & Huang, J. (2017) · MedChemComm · doi:10.1039/c7md00030h · Cited by 73
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 83
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 83
Mitochondrial determinants of cancer health disparities
Choudhury, A. R., & Singh, K. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.001 · Cited by 78
Chen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements
Kim, G. B., Pacheco, D. R. F., Saxon, D. S., Yang, A., Sabet, S., Dutra‐Clarke, M., Levy, R., Watkins, A., Park, H., Akhtar, A. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.013 · Cited by 79
“Finally, K27M tumor cells exhibited many immediate early gene motifs associated with cancer (Pylayeva-Gupta et al., 2011) and motifs for many of the ESC-associated transcription factors (Figure S7U) identified previously in aggressive tumors (Ben-Porath et al.”
Xu, R., Yang, J., Ren, B., Wang, H., Yang, G., Chen, Y., You, L., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572722 · Cited by 78
Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver
Wallace, M. D., Pfefferle, A. D., Shen, L., McNairn, A. J., Cerami, E. G., Fallon, B. L., Rinaldi, V. D., Southard, T. L., Perou, C. M., & Schimenti, J. C. (2012) · Genetics · doi:10.1534/genetics.112.142802 · Cited by 74
Morgan, R. K., Batra, H., Gaerig, V. C., Hockings, J. K., & Brooks, T. A. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.11.004 · Cited by 82
Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer
Bellazzo, A., Minin, G. D., & Collavin, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.134 · Cited by 74
Zhong, X., Zheng, L., Shen, J., Zhang, D., Xiong, M., Zhang, Y., He, X., Tanyi, J. L., Yang, F., Montone, K. T., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-16 · Cited by 73
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward
Khan, M. A., Azim, S., Zubair, H., Bhardwaj, A., Patel, G. K., Khushman, M. M., Singh, S., & Singh, A. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040779 · Cited by 82
“The activating mutations of KRAS are the point mutations at codon G12 (GGT to GAT/ TT/CG ) resulting in the substitution of glycine with aspartate, valine or arginine [47].”
BackgroundInfluentialPalmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras
Liu, P., Jiao, B., Zhang, R., Zhao, H., Zhang, C., Wu, M. H., Li, D., Zhao, X., Qiu, Q., Li, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.293 · Cited by 73
Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells
Mason, J. A., Davison-Versagli, C. A., Leliaert, A. K., Pape, D. J., McCallister, C. M., Zuo, J.-L., Durbin, S., Buchheit, C. L., Zhang, S., & Schafer, Z. T. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.15 · Cited by 74
Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2
Zhou, B., Ho, S. S., Greer, S. U., Spies, N., Bell, J. M., Zhang, X., Zhu, X., Arthur, J. G., Byeon, S., Pattni, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz169 · Cited by 72
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Liu, Z., Parveen, N., Rehman, U., Aziz, A., Sheikh, A., Abourehab, M. A. S., Guo, W., Huang, J., Wang, Z., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01696-5 · Cited by 75
Cregg, J., Pota, K., Tomlinson, A. C. A., Yano, J. K., Marquez, A., Liu, Y., Schulze, C. J., Seamon, K. J., Holderfield, M. T., Wei, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02313 · Cited by 80
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Luo, L.-X., Li, Y., Liu, Z.-Q., Fan, X.-X., Duan, F.-G., Li, R.-Z., Yao, X.-J., Leung, E. L.-H., & Liu, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00199 · Cited by 68
“Among those genes, mutation of KRAS was found in 25–30% of NSCLC (Pylayeva-Gupta et al., 2011).”
BackgroundInfluentialPrakash, P., Hancock, J. F., & Gorfe, A. A. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24786 · Cited by 69
Menin determines K-RAS proliferative outputs in endocrine cells
Chamberlain, C. E., Scheel, D. W., McGlynn, K., Kim, H., Miyatsuka, T., Wang, J., Nguyen, V. Q., Zhao, S., Mavropoulos, A., Abraham, A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69004 · Cited by 72
Ricciuti, B., Leonardi, G. C., Metro, G., Grignani, F., Paglialunga, L., Bellezza, G., Baglivo, S., Mencaroni, C., Baldi, A., Zicari, D., et al. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1115349 · Cited by 65
“KRAS mutation in non-small cell lung cancer KRAS accounts for 90% of RAS mutations in lung adenocarcinomas and represents the most commonly mutated oncogene in non-small cell lung cancer (NSCLC), affecting nearly 25–30% of western patients.[9] In 97% of cases, KRAS mutations involve exon 2 at codon 12; the rest of the…”
BackgroundEukaryotic translation initiation factors and cancer
Ali, M. U., Rahman, M. S. U., Jia, Z., & Jiang, C. (2017) · Tumor Biology · doi:10.1177/1010428317709805 · Cited by 76
HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation?
Amato, J., Madanayake, T. W., Iaccarino, N., Novellino, E., Randazzo, A., Hurley, L. H., & Pagano, B. (2018) · Chemical Communications · doi:10.1039/c8cc03614d · Cited by 75
Neitzel, C., Demuth, P., Wittmann, S., & Fahrer, J. (2020) · Cancers · doi:10.3390/cancers12071731 · Cited by 74
Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation
Wu, B.-K., & Brenner, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.063 · Cited by 67
“RAS proteins are a family of 21 kDa proteins that accomplish signal transduction by coupling receptor engagement to downstream pathway activation (Pylayeva-Gupta et al., 2011).”
BackgroundInfluentialThe complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells
Fey, D., Matallanas, D., Rauch, J., Rukhlenko, O. S., & Kholodenko, B. N. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.011 · Cited by 61
“Despite intensive research over the last four decades, treatments of RAS-driven tumours have limited success [7].”
BackgroundWeng, M.-T., Lee, J.-H., Wei, S.-C., Li, Q., Shahamatdar, S., Hsu, D., Schetter, A. J., Swatkoski, S., Mannan, P., Garfield, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207673110 · Cited by 70
“KRAS is a particularly potent oncogene, because it can activate a number of downstream effector pathways, such as the MAPK pathway, the PI3K pathway, and the Ral GTPases (2, 4).”
BackgroundOkada, M., Shibuya, K., Satō, A., Seino, S., Suzuki, S., Seino, M., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2087 · Cited by 72
“However, in contrast to its well-defined roles in bulk tumor cells [50], the role of Ras mutation in CSCs/CSLCs of K-Ras-mutated tumors has remained unknown so far.”
Identification of the 3-lncRNA Signature as a Prognostic Biomarker for Colorectal Cancer
Liu, S., Cao, Q., An, G., Yan, B., & Lei, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249359 · Cited by 68
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
Weller, C. E., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B. J., Seamon, K. J., et al. (2025) · Science · doi:10.1126/science.ads0239 · Cited by 78
Wright, K. L., Adams, J. R., Liu, J. C., Loch, A. J., Wong, R. G., Jo, C. E. B., Beck, L. A., Santhanam, D. R., Weiss, L. S., Mei, X., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2992 · Cited by 75
“For example, Ras can activate EMT, cellular invasion, motility, survival, angiogenesis and even altered metabolism (50-52).”
BackgroundWnt/β-Catenin and MAPK Signaling: Allies and Enemies in Different Battlefields
Guardavaccaro, D., & Clevers, H. C. (2012) · Science Signaling · doi:10.1126/scisignal.2002921 · Cited by 77
K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions
Chung, J. K., Lee, Y. K., Denson, J.-P., Gillette, W., Alvarez, S. A., Stephen, A. G., & Groves, J. T. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.042 · Cited by 73
Park, E. S., Kim, S., Huang, S., Yoo, J. Y., Körbelin, J., Lee, T. J., Kaur, B., Dash, P. K., Chen, P. R., & Kim, E. (2021) · Annals of Neurology · doi:10.1002/ana.26059 · Cited by 72
“Among the cellular signaling activated by RAS, effects on the RAF/MEK/ERK pathway have been shown in vascular malformations.(10) Mosaic variants were detected in BRAF and MAP2K1, which are found more frequently in high-flow AVMs, whereas mutant PI3K signaling was associated with low-flow vascular malformations, such a…”
BackgroundMUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
Kharbanda, A., Rajabi, H., Jin, C., Alam, M., Wong, K.-K., & Kufe, D. (2014) · Oncotarget · doi:10.18632/oncotarget.2360 · Cited by 65
“Approximately 25% of patients with non-small cell lung cancer (NSCLC) harbor an oncogenic KRAS mutation that is often associated with resistance to conventional and targeted therapies [1].”
BackgroundInfluentialTumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth
Zhou, Y., Yuan, Y., Liu, M., Hu, X., Quan, Y., & Chen, X. (2019) · ExRNA · doi:10.1186/s41544-019-0034-9 · Cited by 63
“KRAS is a prominent oncogene because it can transform normal cells into malignant cells, particularly when harboring an activating mutation in codon 12 or 13 [5].”
BackgroundPlucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
An Evolving Role for DEPTOR in Tumor Development and Progression
Wang, Z., Zhong, J., Inuzuka, H., Gao, D., Shaik, S., Sarkar, F. H., & Wei, W. (2012) · Neoplasia · doi:10.1593/neo.12542 · Cited by 65
“[13] Pylayeva-Gupta Y, Grabocka E, and Bar-Sagi D (2011).”
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P., Priault, M., Chaves, S. R., Moyer, M. P., Oliveira, C., Seruca, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5021 · Cited by 62
RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage
Ramdzan, Z. M., Vadnais, C., Pal, R., Vandal, G., Cadieux, C., Leduy, L., Davoudi, S., Hulea, L., Yao, L., Karnezis, A. N., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001807 · Cited by 62
“Such mutations were previously reported to maintain KRAS in an active GTP-bound state (reviewed in [2]).”
BackgroundColorectal cancer and RASSF family—A special emphasis on RASSF1A
Fernandes, M. S., Carneiro, F., Oliveíra, C., & Seruca, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27696 · Cited by 72
“As transducers of signals from cell surface receptors to intracellular specific effectors, RAS proteins regulate a wide range of biological functions such as cell proliferation, differentiation, survival and death.(9) A particular feature of RAS GTPases is their ability to switch between the inactive GDP-bound and the…”
BackgroundOf Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 72
“The RAS protein is a GTPase driving cellular proliferation, and oncogenic RAS especially promotes progrowth, proangiogenic, and antiapoptotic signals.(195) Specifically for KRAS, this oncogenic activating mutation promotes metastasis in human pancreatic cancer in part by downregulating E-cadherin.”
BackgroundSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
“21037/tlcr-22-639 multiple signaling pathways involved in cell proliferation, differentiation and survival (15,21,22).”
BackgroundPonz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 70
“cellular processes such as proliferation and cell survival (4).”
BackgroundMakino, Y., Hikita, H., Fukumoto, K., Sung, J. H., Sakano, Y., Murai, K., Sakane, S., Kodama, T., Sakamori, R., Kondo, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4390 · Cited by 65
“Recent accumulating evidence suggests that HPCs can malignantly transformanddevelopHCC.”
BackgroundInfluentialLi‐Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29013 · Cited by 72
Barceló, C., Etchin, J., Mansour, M. R., Sanda, T., Morell, M., Lobo, V. J. S.-A., Real, F. X., Capellá, G., Estanyol, J. M., Jaumot, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.041 · Cited by 68
Thyroid C-Cell Biology and Oncogenic Transformation
Cote, G. J., Grubbs, E. G., & Hofmann, M.-C. C. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-22542-5_1 · Cited by 70
Zhang, K., Myllymäki, S.-M., Gao, P., Devarajan, R., Kytölä, V, Nykter, M., Wei, G.-H., & Manninen, A. (2017) · Oncogene · doi:10.1038/onc.2017.177 · Cited by 66
Genomic Hallmarks of Thyroid Neoplasia
Giordano, T. J. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102139 · Cited by 72
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer
Dischinger, P. S., Tovar, E. A., Essenburg, C. J., Madaj, Z. B., Gardner, E. E., Callaghan, M. E., Turner, A. N., Challa, A. K., Kempston, T., Eagleson, B., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0080-8 · Cited by 62
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0494-6 · Cited by 64
“Targeting KRAS downstream effectors has also been challenging, as KRAS regulates a multitude of effectors that contribute to the oncogenic phenotype [2, 3].”
BackgroundSiu, M. K., Abou-Kheir, W., Yin, J. J., Chang, Y.-S., Barrett, B., Suau, F., Casey, O., Chen, W.-Y., Fang, L., Hynes, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1994 · Cited by 62
Zheng, Z.-Y., Tian, L., Bu, W., Fan, C., Gao, X., Wang, H., Liao, Y.-H., Li, Y., Lewis, M. T., Edwards, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.044 · Cited by 64
“Oncogenic RAS mutations are among the most-frequent genetic alterations in human tumors—over 30% of all human tumors contain an oncogenic RAS mutation (Pylayeva-Gupta et al., 2011).”
BackgroundRational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1
Evelyn, C. R., Duan, X., Biesiada, J., Seibel, W. L., Meller, J., & Zheng, Y. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.018 · Cited by 60
“…of NSC-658497 in suppressing SOS1-Ras signaling, mouse embryonic fibroblasts overexpressing an active H-Ras mutant (G12V) known to be GTP-hydrolysis deficient and able to signal independently of SOS1-mediated Ras activation (Pylayeva-Gupta et al., 2011) were generated (Stengel and Zheng, 2012).”
BackgroundIGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling
Wang, Y. A., Sun, Y., Palmer, J. D., Solomides, C., Huang, L., Shyr, Y., Dicker, A. P., & Lü, B. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0390 · Cited by 69
“Because approximately 15% to 25% of patients with lung adenocarcinoma have tumor-associated KRAS mutations and G12D mutation represents 21% of KRAS mutations in NSCLC (22), researchers have developed the Kras transgenic mouse, which develops lung adenomas with 100% penetrance that eventually progress to high-grade ade…”
BackgroundCodon usage regulates human KRAS expression at both transcriptional and translational levels
Fu, J., Dang, Y., Counter, C. M., & Liu, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004908 · Cited by 66
Parker, J. A., & Mattos, C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031427 · Cited by 61
“Molecular dynamics (MD) simulations support these nucleotide-dependent shifts in the conformational ensemble of Ras (Grant et al. 2009; Raimondi et al. 2011).”
BackgroundMahapatra, A. D., Choubey, R., & Datta, B. (2020) · Molecules · doi:10.3390/molecules25235488 · Cited by 65
Liao, C.-F., Lin, S. H., Chen, H. C., Tai, C.-J., Chang, C.-C., Li, L. T., Yeh, C., Yeh, K.-T., Chen, Y.-C., Hsu, T. H., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00205 · Cited by 66
Hu, L., Liang, S., Chen, H., Lv, T., Wu, J., Chen, D., Wu, M. C., Sun, S., Zhang, H., You, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617816114 · Cited by 67
Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., & Buck, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004021 · Cited by 67
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 65
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
“Pathway drug cocktail”: targeting Ras signaling based on structural pathways
Nussinov, R., Tsai, C.-J., & Mattos, C. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.07.009 · Cited by 62
Huber, R., Pietsch, D., Günther, J., Welz, B., Vogt, N., & Brand, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1322-4 · Cited by 70
“In general, Ras proteins are strongly involved in regulating proliferation or tumorigenesis/malignancy [109] and Ras signaling-associated antiproliferative capacity is an important feature by which Ras contributes to monocytic differentiation.”
BackgroundMetabolic reprogramming: a hallmark of viral oncogenesis
Levy, P. L., & Bartosch, B. (2015) · Oncogene · doi:10.1038/onc.2015.479 · Cited by 69
Hodges, T. R., Abbott, J. R., Little, A. J., Sarkar, D., Salovich, J. M., Howes, J. E., Akan, D. T., Sai, J., Arnold, A. L., Browning, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01108 · Cited by 56
Song, M., & Grabocka, E. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_37 · Cited by 67
Self-citationGalectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions
Verkerke, H., Dias‐Baruffi, M., Cummings, R. D., Arthur, C. M., & Stowell, S. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2055-7_1 · Cited by 68
Modeling the mechanisms of biological GTP hydrolysis
Carvalho, A. T. P., Szeler, K., Vavitsas, K., Åqvist, J., & Kamerlin, S. C. L. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.02.027 · Cited by 58
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie · doi:10.1002/ange.201201358 · Cited by 61
Exosomes in Cancer: Diagnostic and Therapeutic Applications
Maqsood, Q., Sumrin, A., Saleem, Y., Wajid, A., & Mahnoor, M. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231215966 · Cited by 68
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
“The active state of KRAS is achieved by a conformational change with the exchange of GTP for GDP [4,6].”
BackgroundIdentifying the Ubiquitin Ligase Complex That Regulates the NF1 Tumor Suppressor and Ras
Hollstein, P. E., & Cichowski, K. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0146 · Cited by 67
“3 INTRODUCTION The Ras pathway is one of the most commonly deregulated pathways in human cancer (1-3).”
E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions
Hosseini, S. M., Okoye, I., Chaleshtari, M. G., Hazhirkarzar, B., Mohamadnejad, J., Azizi, G., Hojjat‐Farsangi, M., Mohammadi, H., Shotorbani, S. S., & Jadidi‐Niaragh, F. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.08.020 · Cited by 68
Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis
Neuhöfer, P., Roake, C. M., Kim, S. J., Lu, R. J., West, R. B., Charville, G. W., & Artandi, S. E. (2021) · Nature · doi:10.1038/s41586-021-03916-2 · Cited by 64
The Importance of Physiologically Relevant Cell Lines for Studying Virus–Host Interactions
Hare, D. N., Collins, S. E., Cuddington, B., & Mossman, K. L. (2016) · Viruses · doi:10.3390/v8110297 · Cited by 63
Enhanced tumorigenicity by mitochondrial DNA mild mutations
Cruz‐Bermúdez, A., Vallejo, C. G., Vicente-Blanco, R. J., Gallardo, M. E., Fernández‐Moreno, M. Á., Quintanilla, M., & Garesse, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3698 · Cited by 60
“Oncogenic Ras activates multiple signaling pathways that affect a wide variety of cellular processes that drive tumorigenesis, stimulating proliferation, suppressing apoptosis, and promoting migration and invasiveness, [35].”
BackgroundMutant HRAS as novel target for MEK and mTOR inhibitors
Kiessling, M. K., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5619 · Cited by 56
“1% in lung and bladder cancer, however, rather infrequent in endometrium and esophageal cancer with about 1% each [31].”
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.